Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection

Summary We evaluated the efficacy and safety of telbivudine (LdT, 600 mg/day) vs control patients (no treatment) in decreasing vertical transmission of HBV, in HBeAg‐positive mothers (HBVDNA >6log10 copies/mL). HBeAg‐positive pregnant women either in the second or third trimester were recruited i...

Full description

Saved in:
Bibliographic Details
Published in:Journal of viral hepatitis 2015-09, Vol.22 (9), p.754-762
Main Authors: Han, G.-R., Jiang, H.-X., Yue, X., Ding, Y., Wang, C.-M., Wang, G.-J., Yang, Y.-F.
Format: Article
Language:English
Subjects:
Adult
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Case-Control Studies
China
DNA, Viral - blood
Female
HBV infection
Hepatitis B - transmission
Hepatitis B Surface Antigens - blood
Humans
Infant
Infant, Newborn
Infectious Disease Transmission, Vertical - prevention & control
Longitudinal Studies
Male
Pregnancy
Prospective Studies
telbivudine
Thymidine - adverse effects
Thymidine - analogs & derivatives
Thymidine - therapeutic use
Treatment Outcome
vertical transmission
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary We evaluated the efficacy and safety of telbivudine (LdT, 600 mg/day) vs control patients (no treatment) in decreasing vertical transmission of HBV, in HBeAg‐positive mothers (HBVDNA >6log10 copies/mL). HBeAg‐positive pregnant women either in the second or third trimester were recruited in a prospective, case–control, open‐label study, at the Second Affiliated Hospital of the Southeast University, China (February 2008‐December 2010). Efficacy (month 7: HBVDNA (+), HBsAg (+) infants) in either the overall group or the treated group and control group was analysed using student's t‐test. Infants were followed for at least 1 year. 362 women received LdT (second trimester n = 257; third trimester n = 105) and 92 were untreated. Before delivery, the mean maternal HBVDNA was 2.73, 2.47, 3.34 and 7.94 log10 copies/mL in the overall, second and third trimester treated and control groups, respectively (P 
ISSN:1352-0504
1365-2893
DOI:10.1111/jvh.12379